AB&B BIO-TECH-B (02627) announced that, following the U.S. Food and Drug Administration's approval of its Investigational New Drug (IND) application in the United States on November 7, 2025, the Center for Drug Evaluation of China's National Medical Products Administration has now approved the IND application for the company's self-developed mRNA RSV vaccine candidate. Respiratory Syncytial Virus (RSV) is a common virus that causes respiratory infections. Particularly in vulnerable populations such as the elderly and individuals with chronic medical conditions, it can develop into severe cases like bronchiolitis or pneumonia. Currently in China, the treatment of RSV infections still relies on broad-spectrum antiviral drugs and symptomatic care. Consequently, there is an urgent need to develop an effective RSV vaccine. mRNA vaccines have demonstrated in clinical research their ability to induce strong cellular immune responses and durable humoral immunity, making them a promising option for protecting the elderly and immunocompromised populations from severe lower respiratory tract infections caused by RSV.